This content was originally shared by a registered user, but access has expired. Create a free account to gain permanent access to all PracticeUpdate content.
Already Have An Account? Log in Now
An Economic Comparison of Healthcare Resource Use and Cost of ddMVAC and Cisplatin vs Gemcitabine and Cisplatin as Neoadjuvant Therapy for Muscle-Invasive Bladder Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
An Economic Analysis Comparing Health Care Resource Use and Cost of Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin Versus Gemcitabine and Cisplatin as Neoadjuvant Therapy for Muscle Invasive Bladder Cancer
Urol. Oncol 2021 Jun 20;[EPub Ahead of Print], K Montazeri, G Dranitsaris, JD Thomas, C Curran, MA Preston, GS Steele, KL Kilbridge, C Mantia, P Ravi, BA McGregor, M Mossanen, G SonpavdeFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.